The Fly reports that in a research note distributed to investors on Monday, investment analysts at Barclays raised their price objective for Grifols (NASDAQ: GRFS) from €8.00 ($8.25) to €9.00 ($9.28).
A couple more brokerages have recently started to offer research on GRFS. The first Grifols-related story on StockNews.com was released on Wednesday, October 12. They rated the stock as a “keep.” Morgan Stanley lowered their price target for Grifols from €20.00 ($20.62) to €13.00 ($13.40) in a research filing on Monday, October 10. JPMorgan Chase & Co. reduced their pricing projection for Grifols from €11.50 ($11.86) to €10.30 ($10.62) in a research statement on September 14. Deutsche Bank Aktiengesellschaft maintained its “hold” rating on Grifols while lowering its price objective from €16.00 ($16.49) to €10.00 ($10.31) in a research report released on Tuesday, October 25. In a research note published on July 25, Jefferies Financial Group started to cover Grifols. They rated the stock as a “keep.” One analyst has assigned a buy rating, one a sell rating, and five analysts have given the company a hold rating. According to Bloomberg data, the company now has an average “Hold” rating and an average target price of $12.52.
NASDAQ GRFS increased $0.27 in trading on Monday to reach $7.80. When compared to the 1,083,755 average volume, 18,800 shares of the stock were exchanged. The company’s current quick, current, and debt-to-equity ratios are 1.20, 0.91, and 2.68, respectively. Grifols’ price ranges from $5.71 to $13.34 over a year, with a fifty-day moving average of $6.94 and a 200-day moving average of $9.37.
Large investors have recently bought and sold shares of the company. Captrust Financial Advisors grew its holding in Grifols by 153.5% during the second quarter. Captrust Financial Advisors increased its direct stock holdings in the biotechnology business by 1,263 shares during the quarter, bringing the total to 2,086 shares, valued at $25,000 as of its current ownership. Brinker Capital Investments LLC purchased additional Grifols shares during the third quarter for roughly $69,000. Creative Planning grew its holdings in Grifols shares by 15.7% during the third quarter. A total of 12,672 shares of the biotechnology business are now directly owned by Creative Planning, with a market value of $78,000, after the company acquired an additional 1,719 shares during the most recent quarter. PNC Financial Services Group Inc. grew its holdings in Grifols shares by 40.0% during the first quarter. PNC Financial Services Group Inc. now owns 10,530 biotechnology company shares worth $122,000, after acquiring an additional 3,010 shares during the most recent quarter. Finally, Alan B. Lancz & Associates Inc. raised its Grifols shares in the second quarter for around $130,000. Institutional investors and hedge funds own 14.62 percent of the company’s stock.
Hemoderivatives are the main medications Grifols, SA purchases, manufactures, prepares, and sells. The company is broken up into divisions for bioscience, healthcare, diagnostics, supplies, and other endeavors. In addition to other cutting-edge therapeutics, the Bioscience division conducts research, develops, produces, and markets plasma-derived pharmaceuticals for patients with life-threatening, frequent, and uncommon conditions.
Read More: Grifols’s (NASDAQ:GRFS) price target is raised by Barclays to €9.00.